PTC Therapeutics - PTCT Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTCT shares.
View PTCT analyst ratings or view top-rated stocks.

9 analysts have issued 12-month price targets for PTC Therapeutics' shares. Their PTCT share price forecasts range from $40.00 to $76.00. On average, they predict the company's stock price to reach $55.50 in the next year. This suggests a possible upside of 32.0% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.

PTC Therapeutics' stock was trading at $39.83 on January 1st, 2022. Since then, PTCT stock has increased by 5.6% and is now trading at $42.06.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our PTCT earnings forecast.

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.78) by $0.11. The biopharmaceutical company had revenue of $139 million for the quarter, compared to the consensus estimate of $118.87 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 983.21% and a negative net margin of 76.28%. The business's revenue was up 68.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.03) EPS.

PTC Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $710.00 million-$750.00 million, compared to the consensus revenue estimate of $726.44 million.

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.03%), RTW Investments LP (7.82%), Armistice Capital LLC (4.03%), State Street Corp (3.93%), Macquarie Group Ltd. (2.17%) and Price T Rowe Associates Inc. MD (2.04%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTCT stock can currently be purchased for approximately $42.06.

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.02 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis.

The company employs 1,177 workers across the globe.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.